Navigation Links
Dendreon Announces Webcast Presentations at Four Upcoming Conferences
Date:2/24/2011

SEATTLE, Feb. 24, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following conferences:

  • Citi Global Health Care Conference, New York, NY on March 2, 2011 at 2:30 p.m. ET
  • RBC Capital Markets' Healthcare Conference, New York, NY on March 3, 2011 at 11:30 a.m. ET
  • Cowen Annual Healthcare Conference, Boston, MA on March 8, 2011 at 11:00 a.m. ET
  • Roth Orange County Growth Stock Conference, Dana Point, CA on March 14, 2011 at 10:00 a.m. PT

The presentations will be webcast live and available for replay from Dendreon's website, www.dendreon.com.  If you are unable to listen to the live webcasts, they will be archived on the site following the presentation.  To access the replay, go to the Investor Relations section of the website.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics.  The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types.  Dendreon's first product, PROVENGE®, was approved by the FDA in April 2010.  Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers.  The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN.  For more information about the Company and its programs, visit http://www.dendreon.com/.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... ... August 10, 2017 , ... SPIE, ... Company Ltd. as its exclusive sales representative for SPIE Journals in Japan. Kinokuniya ... SPIE Digital Library in Japan. , “We look forward to expanding our relationship ...
(Date:8/10/2017)... ... August 10, 2017 , ... ... AptaFluor SAH Methyltransferase Assay , an enabling new high throughput screening (HTS) ... that drive cancer and other debilitating diseases. , Chemical modification of gene expression, ...
(Date:8/8/2017)... ... 2017 , ... HumanZyme Inc., a leading supplier of novel ... launch of HumanKine® Interferon beta (IFN beta) expressed from HEK293 cells. ... innate immune responses against viral and bacterial infection, and have antiproliferative and immunomodulatory ...
(Date:8/8/2017)... ... 08, 2017 , ... Cynvenio Biosystems, Inc. a ... the launch of its second generation PD-L1 expression test. The new blood test ... sensitive and specific profiling and monitoring of PD-L1 expression on lung cancer cells ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
(Date:3/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market is ... next decade to reach approximately $14.21 billion by 2025. ... all the given segments on global as well as regional levels ...
Breaking Biology News(10 mins):